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Abstract
Background: The Acute Respiratory Distress Syndrome (ARDS) is a common cause of respiratory failure in critically
ill patients. Experimental studies suggest that treatment with beta agonists may be helpful in ARDS. The Beta
Agonist Lung Injury TrIal (BALTI-2) is a multicentre, pragmatic, randomised, double-blind, placebo-controlled clinical
trial which aims to determine if sustained treatment with intravenous (IV) salbutamol will improve survival in ARDS.
Methods/Design: Patients fulfilling the American-European Consensus Conference Definition of ARDS will be
randomised in a 1:1 ratio to receive an IV infusion either of salbutamol (15 μg kg ideal body weight
-1 hr
-1)o r
placebo (0.9% sodium chloride solution), for a maximum of seven days. Allocation to randomised groups will use
minimisation to ensure balance with respect to hospital of recruitment, age group (<64, 65-84, >85 years) and
PaO2/FiO2 ratio (≤6.7, 6.8- 13.2, ≥13.3 kPa). Data will be recorded by participating ICUs until hospital discharge, and
all surviving patients will be followed up by post at six and twelve months post randomisation. The primary
outcome is mortality at 28 days after randomisation; secondary outcomes are mortality in ICU, mortality in hospital,
number of ventilator-free days, number of organ failure-free days, mortality at twelve months post-randomisation,
quality of life at six and twelve months, length of stay in ICU, length of stay in hospital, adverse effects
(tachycardia, arrhythmia or other side effects sufficient to stop treatment drug). 1,334 patients will be recruited
from about fifty ICUs in the UK. An economic evaluation will be conducted alongside the trial.
Trial Registration: Current Controlled Trials ISRCTN38366450.
Background
The acute respiratory distress syndrome (ARDS) is a con-
dition characterised by a failure of pulmonary oxygen
exchange due to increased alveolar-capillary permeability
and resultant lung oedema [1]. It can be caused by primary
lung conditions such as aspiration, pneumonia, or can
arise as a complication of non-pulmonary conditions such
as severe sepsis. ARDS is defined by the 1994 American-
European Consensus Conference [2] as the acute onset of
hypoxaemia (PaO2:FiO2 ratio of < 200mm Hg), bilateral
infiltrates on a chest radiograph in the absence of cardio-
genic causes of pulmonary oedema.
ARDS is common, The ALIVE study reported 13.3% of
patients who require mechanical ventilation have ARDS
[3]. Intensive Care Unit (ICU) mortality is estimated at
41-46%, corresponding to about 2,200 deaths per year in
the UK [4,5]. Patients with ARDS consume significantly
more resources than matched patients without ARDS
since they require a longer ICU and hospital stay (median
17 vs 8 days and 31 vs 25 days, respectively) [3], and con-
valescence on the ward and subsequent rehabilitation in
the community. The quality of life after ARDS is signifi-
cantly reduced with 35% unable to return to work 24
months after hospital discharge [6,7]. ARDS has no pri-
mary pharmacological treatments proven to improve out-
come other than supportive care with a lung-protective
ventilator strategy [8].
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potential therapeutic role for b2 agonists in ARDS [9]. In
brief, evidence suggests these agents reduce alveolar
inflammation [10,11], improve endothelial/epithelial bar-
rier function [12,13], accelerate alveolar fluid clearance
[14] and enhance epithelial repair [13,15]. A single centre
phase 2 trial (Beta Agonist Lung Injury TrIal-1; BALTI-
1) investigated the efficacy of intravenous salbutamol on
in-vivo fluid clearance through serial measurement of
extra-vascular lung water in 40 patients with ARDS [16].
The study demonstrated that a sustained intravenous
infusion of salbutamol (15 μg kg ideal body weight
-1 hr
-1)
over 7 days significantly reduced lung water (day 7 lung
water mean (SD), 9.2 (6) vs 13.2 (3) ml kg
-1, P = 0.038)
and plateau airway pressures (23.9(3.8) vs 29.5(7.2) cm
H2O, P = 0.049). This study provided proof of concept
that treatment with intravenous beta agonists may influ-
ence alveolar fluid clearance. The study lacked sufficient
power to measure the effect on other clinical and cost
effectiveness outcomes. The BALTI-2 trial was conceived
to test the hypothesis that sustained treatment with intra-
venous beta agonists in ARDS would improve 28 day
mortality and other clinical and cost effectiveness
outcomes.
Methods/Design
Trial Summary
BALTI-2 is a multicentre, pragmatic, randomised, dou-
ble-blind, placebo-controlled clinical trial. Patients fulfill-
ing the American-European Consensus Conference
Definition of ARDS will be randomised in a 1:1 ratio to
receive an IV infusion either of salbutamol (15 μgk g
ideal body weight
-1 hr
-1) or placebo (0.9% sodium chlor-
ide solution), for a maximum of seven days. Allocation to
randomised groups will use minimisation to ensure bal-
ance with respect to hospital of recruitment, age group
(<64, 65-84, >85 years) and PaO2/FiO2 ratio (≤6.7, 6.8-
13.2, ≥13.3 kPa). The trial will be fully blinded and all
drugs will be packaged identically, so that patients, clini-
cians or investigators will not know which patients are in
each arm. Data will be recorded by participating ICUs
until hospital discharge, and all surviving patients will be
followed up by post at six and twelve months post rando-
misation. The primary outcome is mortality at 28 days
after randomisation; secondary outcomes are mortality in
ICU, mortality in hospital, number of ventilator-free
days, number of non-pulmonary organ failure-free days,
mortality at twelve months post-randomisation, quality
of life at six and twelve months, length of stay in ICU,
length of stay in hospital, adverse effects (e.g. tachycardia,
arrhythmia, lactic acidosis). 1,334 patients will be
recruited from about fifty ICUs in the UK, and an eco-
nomic evaluation will be conducted alongside the trial.
Approvals
The trial is approved by Oxfordshire REC “A” (06/Q1604/
123) and MHRA CTA number 24698/0004/001 and
EudraCT Number: 2006-002647-86. The trial is registered
on the International Standard Randomised Controlled
Trial Registry (ISRCTN38366450). The trial is co-spon-
sored by the University of Warwick and Heart of England
NHS Foundation Trust (http://www.heartofengland.nhs.
uk/ ). The trial is being coordinated by the Warwick Clini-
cal Trials Unit (http://www.warwick.ac.uk/go/ctu). The
trial is funded by the Medical Research Council (MRC)
and will be conducted in accordance with Good Clinical
Practice Guidelines, applicable UK Clinical Trials Regula-
tions and the Standard Operating Procedures of the
Warwick Clinical Trials Unit. The trial will be reported in
line with the Consolidated Standards of Reporting Trials
(CONSORT) 2010 guidelines [17].
Outcome measures
Efficacy
The primary outcome of the study is all cause mortality
28 days after randomisation. Secondary outcomes are
mortality before (first) discharge from ICU; mortality
before (first) discharge from hospital; number of ventila-
tor-free days; number of non-pulmonary organ failure-
free days; duration of ICU and hospital stay; health
related quality of life and mortality at twelve months
post randomisation.
Ventilator free days were defined in accordance with
the ARDSnet criteria [18] as the number of calendar days
after initiating unassisted breathing to day 28 after rando-
misation, assuming a patient survives for at least 48 con-
secutive hours after initiating unassisted breathing.
Un-assisted breathing is defined as one of at least 48 con-
secutive hours of (1) being extubated with face mask,
nasal prong oxygen, or room air (2) T-tube breathing (3)
Tracheostomy mask breathing, CPAP = 5 cm H20w i t h -
out pressure support of intermittent mandatory ventila-
tion assistance.
Non-pulmonary organ failure-free days are defined as
the number of days in the first 28 days after randomiza-
tion that the patient has none of: respiratory support,
cardiovascular support, renal support, or neurological
support. Organ failure was defined according to Critical
Care Minimum Dataset definitions [19].
Safety
The frequency with which the following events occur
will be reported (1) tachycardia sufficient to stop treat-
ment with trial drug (2) new arrhythmia sufficient to
stop treatment with trial drug (3) other side effects suffi-
cient to stop treatment with trial drug (4) serious
adverse events and suspected unexpected serious
adverse reactions.
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Health related quality of life will be measured using EQ-
5D and SF-12 at six and twelve months after randomisa-
tion. Resource use including length of ICU and hospital
stay; health service contacts up to twelve months after
randomisation; out of pocket expenditure and time away
from work.
Eligibility Criteria
Ventilated patients will be screened daily for the devel-
opment of ARDS. Adult (age > 16) patients are eligible
to be included if they are intubated and ventilated
within 72 hours of onset of ARDS. ARDS is defined in
accordance with the American-European consensus con-
ference definition of acute onset of severe hypoxaemic
respiratory failure (PaO2/FiO2 ratio ≤ 26.7 kPa) with
bilateral infiltrates on the chest radiograph in the
absence of clinical evidence of left atrial hypertension.
Patients will be excluded if they are known to be preg-
nant; are receiving current treatment with intravenous
b2-agonists or have a requirement for on-going regular
nebulised/inhaled b2-agonists; are being treated with
b-adrenergic antagonists (“b-blockers”); treatment with-
drawal is imminent; chronic liver disease, defined as
Child-Pugh grade C; enrolled in another clinical trial of
an investigational medicinal product in the last 28 days;
Consent
Consent will be sought from the patients themselves if
this is possible, but it is recognised that in the majority
of cases patients will be unable to give informed consent
due to alterations in their level of consciousness caused
by illness and therapeutic sedation. In this situation
informed consent will be sought from a Personal Legal
Representative or Professional Legal representative. Ret-
rospective consent/consent to continue will be sought
from surviving patients enrolled through consent from a
personal/professional legal representative.
Randomisation
Randomisation will occur via a central telephone rando-
mization service (University of Aberdeen). Randomisa-
tion will be minimised by centre, PaO2/FiO2 ratio (≤6.7,
6.8 to 13.2, ≥13.3kPa), and age (<64, 65 to 84, ≥85
years) because of the expected differences in mortality
among these strata. The randomisation service will allo-
cate a numbered treatment pack to each patient. This
pack will contain all drugs for giving a complete course
of trial treatment to one patient.
Drug supply
Drug treatment packs containing sealed and blinded glass
ampoules of salbutamol sulphate (GlaxoSmithKline) 5 mg
in 5 ml or sodium chloride Injection BP 0.9% w/v (Hameln
Pharmaceuticals Ltd) will be supplied by Bilcare GCS
(Europe) Limited (Elvicta Business Park, Crickhowell,
Powys, UK). All trial drugs will be packaged identically
and identified only by number.
Drug infusions will be administered through a dedi-
cated intravenous line at a rate of 0.075 ml (kg ideal
body weight)
-1 hour
-1 (equivalent to 15 μgs a l b u t a m o l
(kg ideal body weight)
-1 hour
-1) according to the
patients height (table 1). Trial drug infusions should be
started immediately after randomisation. If at the time
of attempting to commence the trial drug the patient’s
heart rate exceeds 140 beats min
-1, the administration
should be delayed until the heart rate is less than 140
beats min
-1 for at least 30 minutes. Every attempt
should be made to complete the treatment infusion
without interruption for a maximum of seven days (i.e.
until 168 hours after randomisation).
Alteration of Infusion Rate
Sinus tachycardia or arrhythmias are known side effects
of intravenous salbutamol administration. If a patient
receiving a trial drug infusion is noted to have tachycar-
dia (heart rate > 140 beats min
-1) or any new arrhythmia
occurs, the dose rate of drug will be adjusted according
to the flow diagram (figure 1). Dose adjustments for
renal or hepatic failure will be driven by the cardiovas-
cular response to the infusion rather than on the degree
of renal or hepatic impairment. Standard anti-arrhyth-
mic therapy will be given if indicated in addition to
alteration of infusion rate.
Infusion Termination Criteria
Termination of the infusion is defined as discontinua-
tion of the trial drug infusion without intention to
restart the infusion at a later time. Trial drug infusion
will be terminated in the following circumstances: death;
heart rate >140 beats min
-1 despite two adjustments in
infusion rate; new arrhythmias despite adjustment in
infusion rate; development of a significant lactic acido-
sis, which in the opinion of the treating clinician is attri-
butable to infusion of the trial drug; 24 hours after
discontinuation of mechanical ventilation (of any sort);
discharge from ICU; discontinuation of active treatment;
request to withdraw from the personal or professional
legal representative; decision by the attending clinician
that the infusion should be discontinued on safety
grounds; 7 days (168 hours) after randomization.
Clinical Management of Patients in the Trial
Patients involved in the BALTI 2 trial will be managed
according to best practice established locally on each
unit. Particular care to monitor electrolytes (K
+,M g
++)
and glucose is required, with electrolyte supplementa-
tion/insulin administered as clinically indicated. The
only specific trial requirement is that patients are not
routinely administered nebulised beta agonists or other
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uncontrolled use of nebulised bronchodilators in the
control group will limit the ability of the trial to detect
a significant difference in outcomes and the use in the
treatment group exposes the patients to a risk of toxi-
city. There is no definitive evidence at the current time
that routine nebulisation of bronchodilators improves
outcomes in patients with acute lung injury. In the
event of acute bronchospasm, where the clinician feels
that a nebulised bronchodilator is required, nebulised
ipratropium bromide may be given. If nebulised ipratro-
pium is insufficient to treat the bronchospasm, then sal-
butamol may be given as a rescue therapy. This will be
recorded on the relevant case report form.
There are no specific guidelines for ventilatory man-
agement. Clinicians will be encouraged to use a low
tidal volume strategy of ventilation based on ideal body
weight. Rescue therapies such as high frequency oscilla-
tory ventilation, nitric oxide and extracorporeal mem-
brane oxygenation can be used according to local policy.
Post Infusion Follow-up
Any patients who remain in the Intensive Care Unit or
High Dependency Unit for more that seven days post
randomisation (the end of the expected drug infusion
period), will continue to be monitored on daily basis
until discharged to a ward. The date and place of hospi-
tal discharge will be obtained from hospital records.
All patients discharged from hospital will be followed-
up six and twelve months after randomisation by postal
questionnaire. The questionnaire will collect data on
disability and health-related quality of life, using the
EQ-5D and SF-12 questionnaires.
Adverse Event Management
BALTI-2 is recruiting a population that is already in a
life-threatening situation, it is therefore expected that
many of the participants will experience serious adverse
events. Events that are expected in this population and
those that are collected as outcomes (e.g. death, organ
failure) of the trial will not be reported as SAEs. Other
SAEs or SUSARs that occur between trial entry and 30
days after the end of the trial drug infusion will be
reported by faxing a serious adverse event log to the
trial co-coordinating centre.
End of Trial
The trial will end when 1334 patients have been recruited
and completed twelve month follow-up. The trial will be
stopped prematurely if: mandated by the Ethics Commit-
tee or the Medicines and Healthcare products Regulatory
Agency (MHRA); following recommendations from the
Data Monitoring and Ethics Committee (DMEC); fund-
ing for the trial ceases.
Sample size
Published estimates of the mortality rate among ARDS
patients range from about 34% to 60%. Two cohort stu-
dies that included UK data estimated that hospital mor-
tality was 53.9% [3] (95% CI 49.0, 58.7%) and 60.9% [4]
(95% CI 55.9, 65.9%). However, it is likely that mortality
has declined since these studies were conducted (1999)
because of the introduction of protective ventilation stra-
tegies after the publication of a large RCT in 2000. From
unpublished ICNARC data for 2005 [5], the hospital
mortality among 37,726 patients with ARDS in the UK
was 41.2%. The primary outcome for BALTI-2 is 28-day
Table 1 Infusion rate according to height (ideal body weight)
Height (cm) Male
IBW
(kg)
Infusion
Rate
(ml hr
-1)
Female
IBW
(kg)
Infusion
Rate
(ml hr
-1)
Height (cm) Male
(IBW)
(kg)
Infusion
Rate
(ml hr
-1)
Female
IBW
(kg)
Infusion
Rate
(ml hr
-1)
146 44.2 3.3 39.7 3.0 174 69.7 5.2 65.2 4.9
148 46.0 3.5 41.5 3.1 176 71.5 5.4 67.0 5.0
150 47.8 3.6 43.3 3.2 178 73.3 5.5 68.8 5.2
152 49.6 3.7 45.1 3.4 180 75.1 5.6 70.6 5.3
154 51.5 3.9 47.0 3.5 182 76.9 5.8 72.4 5.4
156 53.3 4.0 48.8 3.7 184 78.8 5.9 74.3 5.6
158 55.1 4.1 50.6 3.8 186 80.6 6.0 76.1 5.7
160 56.9 4.3 52.4 3.9 188 82.4 6.2 77.9 5.8
162 58.7 4.4 54.2 4.1 190 84.2 6.3 79.7 6.0
164 60.6 4.5 56.1 4.2 192 86.0 6.5 81.5 6.1
166 62.4 4.7 57.9 4.3 194 87.9 6.6 83.4 6.3
168 64.2 4.8 59.7 4.5 196 89.7 6.7 85.2 6.4
170 66.0 5.0 61.5 4.6 198 91.5 6.9 87.0 6.5
172 67.8 5.1 63.3 4.7 200 93.3 7.0 88.8 6.7
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higher than hospital mortality because most deaths will
occur in ICU within a short period after randomisation,
and most patients leave hospital before 28 days. In
BALTI-1 the placebo group 28-day mortality rate was
67% (95% CI 0.45, 0.83). A reasonable conservative esti-
m a t eo ft h e2 8 - d a ym o r t a l i t yt ob ee x p e c t e di nB A L T I - 2
is 40-50%.
Losses to follow-up for the primary outcome are
expected to be very low; in the recently-completed
PAC-Man trial 2.4% of recruited patients were lost
(mainly because of withdrawal of consent) between ran-
domisation and hospital discharge. We have therefore
conservatively assumed a 3% loss of patients for the pri-
mary outcome. Table 2 shows the sample sizes neces-
sary for 80% and 90% power to detect a real risk ratio of
0.80 between the salbutamol and placebo arms, using a
significance level of 0.05.
We will adopt a target sample size of 1334, which will
g i v e9 0 %p o w e rt od e t e c tar i s kr a t i oo f0 . 8i ft h e
Check adequate sedation + seek and correct other 
causes of arrhythmia / sinus tachycardia
Start BALTI -2 infusion at rate A  
If a NEW arrhythmia occurs
Stop infusion
Record ECG
Correct Mg
++/K
+ abnormalities
Inform doctor
Treat arrhythmia as per standard unit protocols.
12 hours later
Reassess the patient
Stop infusion
Record  in CRF. 
Return BALTI-2
drug box to 
pharmacy.
Does the patient still have arrhythmia?
If HR > 140 sustained for > 30 min
or HR > 140 + haemodynamic 
compromise present
Reduce rate to B
Reassess after 1 hour
                 No    Yes
Restart rate B
Further arrhythmia?
Stop infusion
Record ECG
Check adequate sedation
Correct Mg
++/K
+ abnormalities
Inform doctor
Treat arrhythmia as per 
standard unit protocols
Patient should not receive any 
more BALTI-2 study drug. 
Return drug box to pharmacy.
Record in CRF.
Infusion rate A = initial rate
Infusion rate B = rate A/2
Infusion rate C = rate B/2
Continue rate B
HR still > 140?
NO                                                           Yes
Yes
No
HR still > 140?
No                                Yes
Continue rate C
Action
Statement
Instruction
Stop infusion for 12 hours
Restart rate C
Reassess after 1 hour
HR > 140 again?
Figure 1 Tachycardiac/arrhythmia management protocol
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it is 40%, and more than 90% if it exceeds 44%. The 28-
day mortality in the placebo group will be monitored
(via the DMEC), to ascertain whether the assumptions
made in the sample size calculations are correct. If not,
the DMEC will advise on modification to the sample
size.
Statistical Analysis
Primary outcome
Mortality at 28 days post-randomisation will be compared
between the groups by the risk ratio and 95% confidence
interval. Time to death will also be analysed, using survival
analysis methods. The groups will be compared using the
hazard ratio and its 95% confidence interval from a Cox-
proportional hazards model, and a Kaplan-Meier curve
will be used for illustration. The proportional hazard
assumption across treatment arms will be checked graphi-
cally using a log-cumulative hazard plot. This analysis will
be repeated when the long term data are analysed, which
will include survival to 12 months for all participants.
Dichotomous outcomes (death in ICU, death in hospital,
tachycardia, arrhythmia and other side effects) will be
compared using risk ratios and 95% confidence intervals.
For continuous outcomes (duration of ICU and hospital
stay, ventilator-free days and organ failure-free days),
mean differences and 95% confidence interval will be pre-
sented. Time to event outcomes (length of hospital and
ICU stay) will be analysed by survival methods and com-
pared using a hazard ratio and 95% confidence interval.
The SF-12 physical and mental component scores will be
calculated according to the standard methods [1], and
compared between the groups by the mean difference and
95% confidence interval. The EQ-5D will be scored
according to the UK valuation model [2,3], and presented
as the difference in means between the groups with 95%
confidence interval.
Subgroup analyses
Four subgroup analyses are planned to analyse whether
the treatment effect is modified by age, severity of hypox-
aemia before randomisation, aetiology of ARDS, or
APACHE II score. Subgroup analyses will be conducted
for the primary outcome only. It is proposed to replace
the APACHE II score with the APACHE II mortality
risk, which is calculated from the APACHE II score but
also takes into account the underlying condition.
APACHE II scores do not correlate well with mortality
risk as similar scores may occur in patients with different
conditions who have different risks of mortality. This
means that APACHE II score is unlikely to be predictive
of outcome or of treatment effect. The mortality risk
incorporates the underlying condition and is a better
measure of a patient’s “sickness”. It is therefore more
plausible that mortality risk could have a treatment-mod-
ifying effect, and it is preferable to explore this variable’s
relationship to treatment effect. However, APACHE II
score will be retained in the table of baseline characteris-
tics as a descriptor of the population recruited to the
trial. For aetiology of ARDS, the ratio of risk ratios in the
direct and indirect aetiology subgroups will be calculated,
with its 95% confidence interval [6]. We will not attempt
any analysis of subtypes of direct and indirect aetiologies
because the number of patients available is too small and
there is a risk of misleading results. The other three sub-
group-classifying variables are continuous. Although the
BALTI-2 protocol specified categorisations for these vari-
ables, it is proposed to adopt a different approach
because there are problems with categorising continuous
variables. First, there is no clear biological rationale
behind any cut-points, and attempting to use data-driven
procedures to derive “optimal” cut-points is liable to be
seriously misleading. Second, there is good evidence that
any form of categorisation of continuous variables is
potentially misleading, and better methods are available
[7,8]. For these reasons, the potential treatment-modify-
ing factors will not be categorised. Instead, we will use a
regression approach to model the interaction between
the continuous baseline variables and outcomes in each
group. Categorisations of age, severity of hypoxaemia and
APACHE II score will be retained in the table of partici-
pants’ characteristics, to facilitate comparison of the
randomised groups. If there appear to be baseline imbal-
ances that could affect the comparison between the
groups, exploratory analyses will be conducted, adjusting
for these.
Economic Evaluation
Two economic analyses will be undertaken to calculate
the expected incremental cost effectiveness of IV salbu-
tamol compared to standard care in the treatment of
patients with ARDS, admitted to ICUs in the UK.
A within-trial cost effectiveness analysis comparing the
costs and outcomes of patients in each arm of the trial
at 12 months. The perspective for this analysis will be
that of the NHS and Social Services. The primary out-
come for this analysis will be the Quality Adjusted Life
Table 2 Required sample sizes for 80 and 90% power, RR
0.80, 3% losses
Placebo mortality Salbutamol mortality 80% power 90% power
40% 32% 1164 1558
42% 33.6% 1076 1440
44% 35.2% 998 1334
46% 36.8% 926 1238
48% 38.4% 860 1148
50% 40% 798 1068
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5D at 6 and 12 months follow-up. Within ICU resource
use will be identified through a detailed costing study
undertaken at a sample of ICUs recruiting to the trial.
Use of other hospital services will be abstracted from
the trial CRFs. Use of primary, community and social
care services will be recorded via a patient diary com-
pleted at six and 12 months follow-up. Particular effort
will be made to identify place of residence at 12 months
follow-up and whether this is funded by health, social
services or privately. Out of pocket expenditure and
time away from work data will also be collected using
the same patient diary. Unit costs will be obtained from
national sources such as the NHS reference costs and
the PSSRU Unit Costs of Health and Social Care (http://
www.pssru.ac.uk/). Where national costs are not avail-
able, unit costs will be identified in consultation with
finance departments of trusts recruiting to the trial.
Parameter uncertainty will be addressed using probabil-
istic sensitivity analysis. Outputs from the analysis will
include the expected incremental cost effectiveness ratio
(ICER), a scatterplot on the cost effectiveness plane, cost
effectiveness acceptability curve and incremental net
benefit assuming lambda = £20,000 per QALY.
As there is potential for a difference in mortality
between the groups, a lifetime horizon is required to
fully capture the cost and benefits of IV salbutamol
compared to usual care. Therefore, we will construct a
cost effectiveness model with a lifetime time horizon.
This will model the expected long term difference in
QALY’s lived and health and social care resource uti-
lised by two hypothetical cohorts of patients with
ARDS; one treated with IV salbutamol the other not.
The age distribution of these cohorts will reflect the age
profile of ARDS patients actually seen in UK ICUs. Life
expectancy post hospital discharge will be modelled
using national age specific life expectancy data adjusted
to reflect published evidence on the reduced life expec-
tancy of ICU ‘survivors’. Long- term quality of life will
be estimated using published age-specific utility data
adjusted to reflect any published evidence of a diver-
gence in health related quality of life in ICU ‘survivors’.
In the absence of evidence to the contrary, the model
will assume that the treatment modality does not impact
upon the long terms non-ARDS-related health care
costs. Costs and outcomes will be discounted in line
with best practice recommendations at the time of the
analysis. Parameter uncertainty will be addressed using
probabilistic sensitivity analysis. Outputs from the analy-
sis will include the expected ICER, a scatterplot on the
cost effectiveness plane, cost effectiveness acceptability
curve and incremental net benefit assuming lambda =
£20,000 per QALY.
Trial oversight
The day to day management of the trial will be undertaken
by a trial management group comprising chief investiga-
tor, co-investigators and the trial team. Trial oversight will
be provided by a Trial Steering Committee comprised of
investigators and independent members. The committee
will advise upon major decisions such as a need to change
the protocol for any reason; monitoring and supervising
the progress of the trial; Reviewing relevant information
from other sources; Considering recommendations from
the Data monitoring and ethics committee (DMEC);
Informing and advising on all aspects of the trial.
An independent DMEC will be appointed. They will
be responsible for monitoring data accumulating from
the trial. Interim analyses are anticipated to take place
every 12 months during the period of recruitment, or
more frequently if requested by the DMEC. The DMEC
will advise the Chairman of the Steering Committee if,
in their view, the randomised comparisons have pro-
vided both (i) ‘proof beyond reasonable doubt’ that for
all, or some, the treatment is clearly indicated or clearly
contra-indicated and (ii) evidence that might reasonably
be expected to materially influence future patient man-
agement. Following a report from the DMEC, the Steer-
ing Committee will decide what actions, if any, are
required. Unless the DMEC request cessation of the
trial the Steering Committee and the collaborators will
remain ignorant of the interim results.
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